Cover Image

MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open randomized, multicentric, parallel group clinical trial (MASPAC)

Pain symptoms in the upper abdomen and back are prevalent in 80% of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC), where the current standard treatment is a systemic therapy consisting of at least doublet-chemotherapy for fit patients. Palliative low-dose radiotherapy is a well-e...

Full description

Saved in:
Bibliographic Details
Main Authors: Pavic, Matea (Author) , Niyazi, M. (Author) , Wilke, L. (Author) , Corradini, S. (Author) , Vornhülz, M. (Author) , Mansmann, U. (Author) , Al Tawil, A. (Author) , Fritsch, R. (Author) , Hörner-Rieber, Juliane (Author) , Debus, Jürgen (Author) , Guckenberger, M. (Author) , Belka, C. (Author) , Mayerle, Julia (Author) , Beyer, G. (Author)
Format: Article (Journal)
Language:English
Published: 25 January 2022
In: Radiation oncology
Year: 2022, Volume: 17, Pages: 1-10
ISSN:1748-717X
DOI:10.1186/s13014-022-01988-6
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s13014-022-01988-6
Get full text
Author Notes:M. Pavic, M. Niyazi, L. Wilke, S. Corradini, M. Vornhülz, U. Mansmann, A. Al Tawil, R. Fritsch, J. Hörner-Rieber, J. Debus, M. Guckenberger, C. Belka, J. Mayerle and G. Beyer
Description
Summary:Pain symptoms in the upper abdomen and back are prevalent in 80% of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC), where the current standard treatment is a systemic therapy consisting of at least doublet-chemotherapy for fit patients. Palliative low-dose radiotherapy is a well-established local treatment option but there is some evidence for a better and longer pain response after a dose-intensified radiotherapy of the primary pancreatic cancer (pPCa). Stereotactic body radiation therapy (SBRT) can deliver high radiation doses in few fractions, therefore reducing chemotherapy-free intervals. However, prospective data on pain control after SBRT of pPCa is very limited. Therefore, we aim to investigate the impact of SBRT on pain control in patients with mPDAC in a prospective trial.
Item Description:Gesehen am 25.08.2022
Physical Description:Online Resource
ISSN:1748-717X
DOI:10.1186/s13014-022-01988-6

Similar Items